Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)

Cervical and ovarian cancers are well-known causes of death among women in developing countries. There are various technologies to treat cancer cells, but the polyphenolic compound is a natural one and has an anti-cancer effect. Sinensetin is one of them and is found in and citrus fruits. Since comb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of lasers in medical sciences 2021-12, Vol.12 (1), p.e85-e85
Hauptverfasser: Javaheri, Behnam, Esmaeeli Djavid, Gholamreza, Parivar, Kazem, Hekmat, Azadeh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e85
container_issue 1
container_start_page e85
container_title Journal of lasers in medical sciences
container_volume 12
creator Javaheri, Behnam
Esmaeeli Djavid, Gholamreza
Parivar, Kazem
Hekmat, Azadeh
description Cervical and ovarian cancers are well-known causes of death among women in developing countries. There are various technologies to treat cancer cells, but the polyphenolic compound is a natural one and has an anti-cancer effect. Sinensetin is one of them and is found in and citrus fruits. Since combination therapy is more effective than drug treatment alone, in this study, we investigated combination therapy using sinensetin and low-level laser therapy (LLLT) to enhance treatment. The cancer cells purchased from Pasteur Institute, Iran, were cultured. The cells were treated with various concentrations of sinensetin (0.1-1-10-50,150 µg/mL for 24 hours), wavelengths of laser therapy (660 nm) and power density (3 J/cm2) for different times)30, 60, and 90 seconds) separately. Furthermore, sensitivity of cells to sinensetin, LLLT and combined therapy was determined by clonogenic assays. To measure DNA damage and repair at individual cell level used comet assay. To examine the intracellular generation of reactive oxygen species used 2',7'-dichlorodihydrofluorescein (DCFH) as an intracellular probe. To analyze data we used SPSS software and comparison between groups was used (ANOVA) and test statistical analyses were performed using SPSS 17 software. Data are presented as means - standard error of mean. The level of statistical significance was set at a two-tailed value of 0.05. All tests were performed in triplicate. Our results demonstrated that the doubling time for CHO is more than Hella cells, with 20.7 and 27.7 h for each cell respectively. The pretreatments (first LLLT, then sinensetin) can decrease the viability of both cell lines more than the first treatment (sinensetin + LLLT). In the clonogenic assay, the pretreatment of cells with LLLT and Sinensetin significantly reduced the surviving fraction of both cell lines. MTT results showed that pretreatment with LLLT and Sinensetin can increase cell death compared to Sinensetin and LLLT alone. Production of ROS within the cell was enhanced with LLLT + sinensetin. Our result indicated that combined therapy with LLLT and Sinensetin can treat CHO and Hela cells better than the other groups. Combination treatment with sinensetin-LLLT and the other treatment means, sinensetin and LLLT alone, did not change the cell viability significantly.
doi_str_mv 10.34172/jlms.2021.85
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2628676988</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-1daabb16f48c14ea1bc5488d055aa21f46c377c3b9007d27d2c3a331920040183</originalsourceid><addsrcrecordid>eNpVUU1LxDAQDaKoqEevkuPuoWs-2ia9CFLUFYp7cD2HaZpqpU3WpKv47826rugQmCHz8iZvHkLnlMx4SgW7fO2HMGOE0ZnM9tAxY0wmuWB0P9aEyKQQkh-hsxBeSQxBeMqKQ3TEM5plVJBjFG7a1ugRuxZX7iOpzLvpcQXBeLx8MR5Wnxhsgx87a2wwY2fxpHRD3VkYO2fxuMVMcayX68F5XJq-D3gyNz1Mv58-OD9Av7sv54vpKTpooQ_m7CefoKfbm2U5T6rF3X15XSWaSzEmtAGoa5q3qdQ0NUBrnaVSNiTLABht01xzITSvi6isYfFoDpzTIipPCZX8BF1teVfrejCNNnb00KuV7wbwn8pBp_53bPeint27kpLHvfFIMPkh8O5tbcKohi7oKASsceugWM5kLvJCbmYlW6j2LgRv2t8xlKhvr9TGK7XxSsks4i_-_u0XvXOGfwFzZo8w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2628676988</pqid></control><display><type>article</type><title>Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Javaheri, Behnam ; Esmaeeli Djavid, Gholamreza ; Parivar, Kazem ; Hekmat, Azadeh</creator><creatorcontrib>Javaheri, Behnam ; Esmaeeli Djavid, Gholamreza ; Parivar, Kazem ; Hekmat, Azadeh</creatorcontrib><description>Cervical and ovarian cancers are well-known causes of death among women in developing countries. There are various technologies to treat cancer cells, but the polyphenolic compound is a natural one and has an anti-cancer effect. Sinensetin is one of them and is found in and citrus fruits. Since combination therapy is more effective than drug treatment alone, in this study, we investigated combination therapy using sinensetin and low-level laser therapy (LLLT) to enhance treatment. The cancer cells purchased from Pasteur Institute, Iran, were cultured. The cells were treated with various concentrations of sinensetin (0.1-1-10-50,150 µg/mL for 24 hours), wavelengths of laser therapy (660 nm) and power density (3 J/cm2) for different times)30, 60, and 90 seconds) separately. Furthermore, sensitivity of cells to sinensetin, LLLT and combined therapy was determined by clonogenic assays. To measure DNA damage and repair at individual cell level used comet assay. To examine the intracellular generation of reactive oxygen species used 2',7'-dichlorodihydrofluorescein (DCFH) as an intracellular probe. To analyze data we used SPSS software and comparison between groups was used (ANOVA) and test statistical analyses were performed using SPSS 17 software. Data are presented as means - standard error of mean. The level of statistical significance was set at a two-tailed value of 0.05. All tests were performed in triplicate. Our results demonstrated that the doubling time for CHO is more than Hella cells, with 20.7 and 27.7 h for each cell respectively. The pretreatments (first LLLT, then sinensetin) can decrease the viability of both cell lines more than the first treatment (sinensetin + LLLT). In the clonogenic assay, the pretreatment of cells with LLLT and Sinensetin significantly reduced the surviving fraction of both cell lines. MTT results showed that pretreatment with LLLT and Sinensetin can increase cell death compared to Sinensetin and LLLT alone. Production of ROS within the cell was enhanced with LLLT + sinensetin. Our result indicated that combined therapy with LLLT and Sinensetin can treat CHO and Hela cells better than the other groups. Combination treatment with sinensetin-LLLT and the other treatment means, sinensetin and LLLT alone, did not change the cell viability significantly.</description><identifier>ISSN: 2008-9783</identifier><identifier>EISSN: 2228-6721</identifier><identifier>DOI: 10.34172/jlms.2021.85</identifier><identifier>PMID: 35155170</identifier><language>eng</language><publisher>Iran: Laser Application in Medical Sciences Research Center</publisher><subject>Original</subject><ispartof>Journal of lasers in medical sciences, 2021-12, Vol.12 (1), p.e85-e85</ispartof><rights>Copyright © 2021 J Lasers Med Sci.</rights><rights>Copyright © 2021 J Lasers Med Sci 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-1daabb16f48c14ea1bc5488d055aa21f46c377c3b9007d27d2c3a331920040183</citedby><orcidid>0000-0001-8083-3990 ; 0000-0003-0123-1575 ; 0000-0002-8577-9476 ; 0000-0002-7235-2852</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837833/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837833/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35155170$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javaheri, Behnam</creatorcontrib><creatorcontrib>Esmaeeli Djavid, Gholamreza</creatorcontrib><creatorcontrib>Parivar, Kazem</creatorcontrib><creatorcontrib>Hekmat, Azadeh</creatorcontrib><title>Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)</title><title>Journal of lasers in medical sciences</title><addtitle>J Lasers Med Sci</addtitle><description>Cervical and ovarian cancers are well-known causes of death among women in developing countries. There are various technologies to treat cancer cells, but the polyphenolic compound is a natural one and has an anti-cancer effect. Sinensetin is one of them and is found in and citrus fruits. Since combination therapy is more effective than drug treatment alone, in this study, we investigated combination therapy using sinensetin and low-level laser therapy (LLLT) to enhance treatment. The cancer cells purchased from Pasteur Institute, Iran, were cultured. The cells were treated with various concentrations of sinensetin (0.1-1-10-50,150 µg/mL for 24 hours), wavelengths of laser therapy (660 nm) and power density (3 J/cm2) for different times)30, 60, and 90 seconds) separately. Furthermore, sensitivity of cells to sinensetin, LLLT and combined therapy was determined by clonogenic assays. To measure DNA damage and repair at individual cell level used comet assay. To examine the intracellular generation of reactive oxygen species used 2',7'-dichlorodihydrofluorescein (DCFH) as an intracellular probe. To analyze data we used SPSS software and comparison between groups was used (ANOVA) and test statistical analyses were performed using SPSS 17 software. Data are presented as means - standard error of mean. The level of statistical significance was set at a two-tailed value of 0.05. All tests were performed in triplicate. Our results demonstrated that the doubling time for CHO is more than Hella cells, with 20.7 and 27.7 h for each cell respectively. The pretreatments (first LLLT, then sinensetin) can decrease the viability of both cell lines more than the first treatment (sinensetin + LLLT). In the clonogenic assay, the pretreatment of cells with LLLT and Sinensetin significantly reduced the surviving fraction of both cell lines. MTT results showed that pretreatment with LLLT and Sinensetin can increase cell death compared to Sinensetin and LLLT alone. Production of ROS within the cell was enhanced with LLLT + sinensetin. Our result indicated that combined therapy with LLLT and Sinensetin can treat CHO and Hela cells better than the other groups. Combination treatment with sinensetin-LLLT and the other treatment means, sinensetin and LLLT alone, did not change the cell viability significantly.</description><subject>Original</subject><issn>2008-9783</issn><issn>2228-6721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LxDAQDaKoqEevkuPuoWs-2ia9CFLUFYp7cD2HaZpqpU3WpKv47826rugQmCHz8iZvHkLnlMx4SgW7fO2HMGOE0ZnM9tAxY0wmuWB0P9aEyKQQkh-hsxBeSQxBeMqKQ3TEM5plVJBjFG7a1ugRuxZX7iOpzLvpcQXBeLx8MR5Wnxhsgx87a2wwY2fxpHRD3VkYO2fxuMVMcayX68F5XJq-D3gyNz1Mv58-OD9Av7sv54vpKTpooQ_m7CefoKfbm2U5T6rF3X15XSWaSzEmtAGoa5q3qdQ0NUBrnaVSNiTLABht01xzITSvi6isYfFoDpzTIipPCZX8BF1teVfrejCNNnb00KuV7wbwn8pBp_53bPeint27kpLHvfFIMPkh8O5tbcKohi7oKASsceugWM5kLvJCbmYlW6j2LgRv2t8xlKhvr9TGK7XxSsks4i_-_u0XvXOGfwFzZo8w</recordid><startdate>20211227</startdate><enddate>20211227</enddate><creator>Javaheri, Behnam</creator><creator>Esmaeeli Djavid, Gholamreza</creator><creator>Parivar, Kazem</creator><creator>Hekmat, Azadeh</creator><general>Laser Application in Medical Sciences Research Center</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8083-3990</orcidid><orcidid>https://orcid.org/0000-0003-0123-1575</orcidid><orcidid>https://orcid.org/0000-0002-8577-9476</orcidid><orcidid>https://orcid.org/0000-0002-7235-2852</orcidid></search><sort><creationdate>20211227</creationdate><title>Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)</title><author>Javaheri, Behnam ; Esmaeeli Djavid, Gholamreza ; Parivar, Kazem ; Hekmat, Azadeh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-1daabb16f48c14ea1bc5488d055aa21f46c377c3b9007d27d2c3a331920040183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Javaheri, Behnam</creatorcontrib><creatorcontrib>Esmaeeli Djavid, Gholamreza</creatorcontrib><creatorcontrib>Parivar, Kazem</creatorcontrib><creatorcontrib>Hekmat, Azadeh</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of lasers in medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javaheri, Behnam</au><au>Esmaeeli Djavid, Gholamreza</au><au>Parivar, Kazem</au><au>Hekmat, Azadeh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)</atitle><jtitle>Journal of lasers in medical sciences</jtitle><addtitle>J Lasers Med Sci</addtitle><date>2021-12-27</date><risdate>2021</risdate><volume>12</volume><issue>1</issue><spage>e85</spage><epage>e85</epage><pages>e85-e85</pages><issn>2008-9783</issn><eissn>2228-6721</eissn><abstract>Cervical and ovarian cancers are well-known causes of death among women in developing countries. There are various technologies to treat cancer cells, but the polyphenolic compound is a natural one and has an anti-cancer effect. Sinensetin is one of them and is found in and citrus fruits. Since combination therapy is more effective than drug treatment alone, in this study, we investigated combination therapy using sinensetin and low-level laser therapy (LLLT) to enhance treatment. The cancer cells purchased from Pasteur Institute, Iran, were cultured. The cells were treated with various concentrations of sinensetin (0.1-1-10-50,150 µg/mL for 24 hours), wavelengths of laser therapy (660 nm) and power density (3 J/cm2) for different times)30, 60, and 90 seconds) separately. Furthermore, sensitivity of cells to sinensetin, LLLT and combined therapy was determined by clonogenic assays. To measure DNA damage and repair at individual cell level used comet assay. To examine the intracellular generation of reactive oxygen species used 2',7'-dichlorodihydrofluorescein (DCFH) as an intracellular probe. To analyze data we used SPSS software and comparison between groups was used (ANOVA) and test statistical analyses were performed using SPSS 17 software. Data are presented as means - standard error of mean. The level of statistical significance was set at a two-tailed value of 0.05. All tests were performed in triplicate. Our results demonstrated that the doubling time for CHO is more than Hella cells, with 20.7 and 27.7 h for each cell respectively. The pretreatments (first LLLT, then sinensetin) can decrease the viability of both cell lines more than the first treatment (sinensetin + LLLT). In the clonogenic assay, the pretreatment of cells with LLLT and Sinensetin significantly reduced the surviving fraction of both cell lines. MTT results showed that pretreatment with LLLT and Sinensetin can increase cell death compared to Sinensetin and LLLT alone. Production of ROS within the cell was enhanced with LLLT + sinensetin. Our result indicated that combined therapy with LLLT and Sinensetin can treat CHO and Hela cells better than the other groups. Combination treatment with sinensetin-LLLT and the other treatment means, sinensetin and LLLT alone, did not change the cell viability significantly.</abstract><cop>Iran</cop><pub>Laser Application in Medical Sciences Research Center</pub><pmid>35155170</pmid><doi>10.34172/jlms.2021.85</doi><orcidid>https://orcid.org/0000-0001-8083-3990</orcidid><orcidid>https://orcid.org/0000-0003-0123-1575</orcidid><orcidid>https://orcid.org/0000-0002-8577-9476</orcidid><orcidid>https://orcid.org/0000-0002-7235-2852</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2008-9783
ispartof Journal of lasers in medical sciences, 2021-12, Vol.12 (1), p.e85-e85
issn 2008-9783
2228-6721
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837833
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Effect of Low-Level Laser Therapy and Sinensetin (Combination therapy) on Tumor Cells (Hela) and Normal Cells (CHO)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A28%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Low-Level%20Laser%20Therapy%20and%20Sinensetin%20(Combination%20therapy)%20on%20Tumor%20Cells%20(Hela)%20and%20Normal%20Cells%20(CHO)&rft.jtitle=Journal%20of%20lasers%20in%20medical%20sciences&rft.au=Javaheri,%20Behnam&rft.date=2021-12-27&rft.volume=12&rft.issue=1&rft.spage=e85&rft.epage=e85&rft.pages=e85-e85&rft.issn=2008-9783&rft.eissn=2228-6721&rft_id=info:doi/10.34172/jlms.2021.85&rft_dat=%3Cproquest_pubme%3E2628676988%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2628676988&rft_id=info:pmid/35155170&rfr_iscdi=true